Founded in 1908, Fette Compacting has a brand development history of over 100 years and is a globally renowned leading enterprise in the solid dosage form industry.
Fette Compacting’s success story in China has began in 2004 with just 20 employees and has grown into a leading manufacturer of tablet press， with around 70-80% of the high-end market share in China. With advanced tablet production and continuous manufacturing technologies, Fette Compacting has been deeply involved in the Chinese market for two decades, witnessing the rapid development of the Chinese pharmaceutical industry.
As we celebrate 20 years of development in China, Fette Compacting is globally launching the new generation p Series — the F30p tablet press. On this occasion, we had the privilege of interviewing Dr. Andreas Risch, General Manager of Fette Compacting China, who introduced us to Fette Compacting’s development history in China and its advanced solid dosage form production technology.
1.Can you introduce the history and future vision of Fette Compacting in China?
Dr. Andreas Risch: In the year 2004, we have founded Fette Compacting China, as the 3rd subsidiary in our group. Fette Compacting was one of the first medium-sized German machine manufacturers in 2004 to invest in Nanjing. With roughly 20 employees, when only 2% of the Foreign Direct Investments in China originated from Germany. We were part of it. Retrospectively it has been a very wise decision.
The Chinese Pharma Market was ranked at position no. 17 on the global market. Today China is the 3rd biggest pharma market in the world. It shows what a dramatic change has taken place within the last twenty years in China and in the world.
Fette Compacting is coming from a machine maker of excellent tablet press solutions, and we are now on the way to a process technology provider for powder formulation and tableting in the Pharma and Nutrition industry.
Our latest Group Strategy underlines this and is supposed to bring even more benefits to our customers: we provide significant added value through in-depth consultancy and support with experience of over 6,000 installations covering nearly all OSD products worldwide (and more than 720 machines are running in the Chinese market）, enabling the pharma industry to increase production efficiency without waste, to shorten the time to market and to be most successful in all aspects of tableting from Lab to production.
2. As a leading manufacturer of tablet press equipment in China, how does Fette Compacting view the role of the Chinese market in its global strategy?
Dr. Andreas Risch: Looking back on 20 years of successful development in China, developed from a Sales Service and assembly hub for China at the beginning; in the meanwhile, grown to a full scope Technology and Production company that is one cornerstone of the global Fette Compacting Group, providing high-quality Machines, services and competence for Chinese and global customers. Today, besides our Germany facility, China is our 2nd production site around the world. For us, it is a very important pillar in our strategy development, and we understand the Chinese market is very important.
3. Compared to traditional tablet presses, what pain points does the new p Series address? What are the application scenarios for this series of tablet presses?
Dr. Andreas Risch: The Chinese pharmaceutical industry faces deep transformations due to healthcare reforms and centralized procurement. At the crossroads of an ever-changing international market, Fette Compacting faces new challenges in rapidly creating new production capacities to address these changes.
Over time, even Fette Compacting’s proud traditional flagship products have shown diminishing margi...
(All Rights Reserved)